Q fever
Conditions
Interventions
Coxiella burnetii
Immune response
T cell epitopes
Vaccine
Sponsors
Massachusetts General Hospital
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Participants in this study have been exposed to Coxiella burnetii resulting in chronic Q fever, resolved acute Q fever, or have a strong T cell mediated immune response to Coxiella without having any clinical symptoms. A control group consisting of people without a Cb immune response will be recruited. In addition, a group that was vaccinated with Q-VAX in 2011 in the RIVM/GGD campaign for people with an increased risk of chronic Q fever will be included.
Exclusion criteria
Exclusion criteria: blood-transmissable infectious disease known immune disease use of immune suppressives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining ex vivo the effect of Cb-derived T cell epitopes on IFN-γ production in blood of healthy volunteers, subjects with active or resolved (chronic) Q fever infection, and subjects vaccinated with Q-VAX. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Comparison of T cell responses in subjects with and without acute disease. • Biomarker discovery to differentiate protective, non-protective, and reactogenic epitopes and responses. • Determine the role of anti-Coxiella antibody formation on T cell responses. | — |
Countries
Netherlands, United States of America
Outcome results
None listed